Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$9.01
-$0.34(-1.95%)
At close: 4:00 PM EST
$9.01
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$8.46 - $26.50
Previous CloseN/A
Volume45.37K
Average Volume (3M)76.91K
Market Cap
$244.94M
Enterprise Value$127.81M
Total Cash (Recent Filing)$160.32M
Total Debt (Recent Filing)$13.35M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Nov 06, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding26,002,043
10 Day Avg. Volume78,090
30 Day Avg. Volume76,909
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue124.57
Enterprise Value/Gross Profit124.57
Enterprise Value/Ebitda-1.68
Forecast
1Y Price Target
$40.20Price Target Upside346.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessRecent 12mo Phase 2b data demonstrated unprecedented durability and left a new efficacy watermark, which we viewed as further support for Descartes-08's use case in I&I.
Financial PerformanceTotal 2Q25 net income was 15.9M vs. a net loss estimate of $17.5M.
Financial StabilityCartesian management stated that its current cash should fund operations into mid-2027, past the conclusion of the AURORA trial.
Bears Say
Clinical Trial RisksRisks include, but are not limited to: (1) delays in moving candidates through trials; (2) failure to generate favorable clinical data, particularly with Descartes-08 in MG.
Treatment ChallengesNon-responders to current standard of care are at high risk of organ failure and even death, with a lack of disease-modifying therapies available.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $8.46 and its highest was $26.50 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $244.94M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Aug 07, 2025. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of -$0.803 by $1.303.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 26,002,043 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of $0.5 in its last earnings report, beating expectations of -$0.803. Following the earnings report the stock price went down -6.56%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.20 (346.17% Upside)
$40.20 (346.17% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.47%
12-Months-Change
Fundamentals
Return on Equity
-938.38%
Trailing 12-Months
Asset Growth
11.83%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$40.20
▲(346.17% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―